[7-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy]-2-oxoquinolin-1-yl]methyl 2,3-dimethylbutanoate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: [7-[4-[4-(2,3-Dichlorophenyl)piperazin-1-yl]butoxy]-2-oxoquinolin-1-yl]methyl 2,3-dimethylbutanoate
• 英文别名: [7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-2-oxoquinolin-1-yl]methyl 2,3-dimethylbutanoate
• 化学式: C₃₀H₃₇Cl₂N₃O₄
• 分子量: 574.5
• InChiKey: XLTCIOUELWYQOA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.9
• 重原子数：
  39
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  62.3
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• Heterocyclic compounds for the treatment of neurological and psychological disorders
  申请人：Alkermes Pharma Ireland Limited

  公开号：US10351529B2

  公开（公告）日：2019-07-16

  Lactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.

  公开了式 I 的内酰胺化合物及其在治疗神经和精神疾病（包括精神分裂症、躁郁症、焦虑症和失眠症）方面的用途。
• HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS
  申请人：Alkermes Pharma Ireland Limited

  公开号：US20190084937A1

  公开（公告）日：2019-03-21

  Lactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.